hMPV M2-2 PDZ Motif Mutations for Attenuated Vaccine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for human metapneumovirus (hMPV) and human respiratory syncytial virus (hRSV) are ineffective and can even increase disease severity, with no approved vaccines existing to date, necessitating the development of effective therapeutic approaches against these pathogens.
Innovation Solution
Development of live attenuated Pneumoviridae strains with mutations in the PDZ-binding motif of the M2-2 protein to disrupt immune evasion, maintaining immunogenicity and protective properties while reducing virulence, and the use of these strains in immunogenic compositions for immunoprotection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If live attenuated Pneumoviridae strains with mutations in PDZ-binding motif of M2-2 protein are developed to disrupt immune evasion, then immunogenicity and protective properties are maintained while virulence is reduced, but the complexity of vaccine development increases
Solution Approach 1:
The M2-2 protein is segmented into functional domains, with specific mutations introduced in the PDZ-binding motif region while preserving other functional regions. This targeted segmentation allows disruption of immune evasion function while maintaining essential viral functions for immunogenicity.
Solution Approach 2:
Specific amino acid changes are introduced at the PDZ-binding motif location (local region) of the M2-2 protein, creating a localized modification that disrupts PDZ protein interactions without affecting the overall structure and function of the protein. This local quality change achieves virulence reduction while preserving immunogenicity.
2Object-affected harmful factors
If mutations are introduced in the PDZ-binding motif of M2-2 protein to reduce virulence, then protection against hMPV and hRSV infections is improved, but the manufacturing precision requirements increase
Solution Approach 1:
Specific amino acid parameters in the PDZ-binding motif are changed through targeted mutations. The patent identifies and modifies specific residue positions in the M2-2 protein sequence, changing chemical properties at these locations to disrupt PDZ protein binding while maintaining precise control over the mutation process through molecular biology techniques.
3Reliability
If live attenuated strains are used to elicit robust immune responses with enhanced cytokine and chemokine production, then protection against respiratory infections is improved, but the risk of disease severity increase remains
Solution Approach 1:
The patent converts the harmful immune evasion function of the M2-2 protein into a beneficial effect by mutating its PDZ-binding motif. This disruption prevents the virus from suppressing immune responses, thereby enhancing cytokine and chemokine production and immune cell activation in a controlled manner that provides protection without excessive pathology.
Solution Approach 2:
The virulence parameters of the virus are precisely adjusted through mutations in the M2-2 protein, creating an attenuated strain that elicits sufficient immune responses for protection while maintaining safety. The parameter changes in the PDZ-binding motif specifically modulate the balance between immunogenicity and virulence.
Data Source
AI summary
The present application generally relates to the development of live attenuated Pneumoviridae strains suitable for use as a vaccine. Particularly, human metapneumovirus (hMPV) ΔM2-2 strains (rhMPV-E30M31 and rhMPV-E40L42D44) containing point mutations in a PDZ motif of M2-2, which results in a strain that is both attenuated and immunogenic and, notably, maintains the function of F and G proteins. These live attenuated hMPV strains should be suitable for use in a vaccine capable of providing protection against respiratory infection elicited by hMPV. Additionally, human respiratory syncytial virus (hRSV) strains containing point mutations in a PDZ motif of M2-2 should also be suitable for use as a vaccine capable of providing protection against respiratory infection elicited by hRSV. These Pneumoviridae strains should be useful in vaccines for use in humans and animals, e.g., companion animals and livestock, in treating or providing immunoprotection against respiratory infections.